Article | November 11, 2026

Rethinking Fixed Processes In Cell Therapy Development

Process development rarely runs in a straight line. Expansion yields shift between stages, dose targets move, and source material varies by patient in autologous programs and by donor in allogeneic ones, sometimes mid-program. Most processing equipment runs fixed protocols, so the process bends to fit the tool.

The workarounds that follow rarely feel like big decisions: a manual step at the bench, a second device, a compromise that is close enough. Each adds run-to-run variability, and a process built on them is harder to document, transfer and defend to quality.

Often the constraint is not the hardware itself but the rigid logic governing how the machine operates. Five criteria give process development teams a way to test any processing platform, along with a look at what changes when the process is designed around the cells instead of the equipment.

Get the full article for a practical standard to hold your next platform to.

Access The Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online